Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

Harsányi, András; Csanádi, Marcell; Márky, Kristóf; Vincziczki, Áron Zoltán; Kaló, Zoltán; Inotai, András

doi:10.1080/14737167.2019.1667232

Cited by 11 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The growth in the utilisation of the biosimilar in Hungary is also welcomed as this was not the case with biosimilars for infliximab and rituximab [124,125]. However, there are now ongoing reforms in Hungary to encourage physicians to start patients on the least expensive biosimilar as well as the reference pricing system with patients required to fund the difference in prices between the originator and any biosimilar themselves [126].…”

Section: Utilisation Of Insulinmentioning

confidence: 99%

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

Godman

Władysiuk

McTaggart

et al. 2021

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results. Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed.

show abstract

Section: Utilisation Of Insulinmentioning

confidence: 99%

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

Godman

Władysiuk

McTaggart

et al. 2021

BioMed Research International

Self Cite

View full text Add to dashboard Cite

show abstract

“…The potential benefit of biosimilars in improving patient access to biological therapies were described in previous studies [27,29]. The research study carried out by Harsányi et al could not confirm the assumption that the advent of biosimilar products enhanced the availability of the biological therapies for the patients [26]. Kaló et al described the two conflicting factors influencing the cost-saving potential of off-patent pharmaceutcials, namely price erosion and drug utilisation, therefore, we also included the DOT based evaluation in our study [28].…”

Section: Discussionmentioning

confidence: 95%

“…Initially, it was of utmost importance to prioritise the concept of biological or biosimilar drugs. [1] The introduction of biosimilar products to the drug market made it possible to choose from multiple available drugs thus generating a price competition which inevitably means a significant decrease in source outflow for the social security authorities [2,[26][27][28][29].…”

Section: Introductionmentioning

confidence: 99%

The long-term effects of the biolicit procedure for original and biosimilar GCSF and EPO products in Hungary

Hornyák

Nagy

Vathy-Fogarassy

et al. 2021

APH

View full text Add to dashboard Cite

Aim: We aimed to analyse the long-term effects of the biosimilar bids of NEAK regarding GCSF and EPO drugs. Data and Methods: Our analysis is based on the data derived from the nationwide pharmaceutical database of NEAK. The treatment days and reimbursement figures of 12 months periods has been compared, from 01.07.2011-30.06.2014. and 01.07.2017.-30.06.2019. Results: In the 12 months preceding the price competition bid of biosimilar products 13974 patients received G-CSF, 7.49 billion HUF health insurance reimbursement has been paid, 5 years later the turnover of the product increased (314760, 340100 DOT value), whereas the reimbursement decreased (2.03 billion HUF, 1.95 billion HUF respectively). 12 months before the biosimial price competition, 4167 patients were treated with erythropoietin, resulting in 2.33 billion HUF of reimbursements, in the last 2 years the turnover increased (48727, 50813 DOT value respectively) with decreased reimbursement (1.004 billion HUF, 1.002 billion HUF respectively). Conclusions: The long-range analyses price competition bid of biosimilar products revealed that in case of products the health insurance reimbursement decreased despite the elevated turnover in a longer period as well. During the years following the start of the price competition bid the switch from original products to biosimilars could be observed.

show abstract

“…However, the specific plan for biosimilar policies can be defined differently in countries experiencing significant resource limitations, where access to expensive reference medicines is limited ( Brodszky et al, 2016 ; Inotai and Kaló, 2019 ). In countries with limited or no access to reference medicines, the key benefit of biosimilars is not related to their cost-saving potential; therefore, the target for biosimilar policies should be characterized from an investment point of view ( Elek et al, 2017 ; Harsányi et al, 2020 ) by increasing patient access and by improving the number of treated patients ( Inotai et al, 2018 ; Ferrario et al, 2020 ).…”

Section: Discussionmentioning

confidence: 99%

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

Tesař

Golias²,

Masaryková

et al. 2021

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Background: The aim of this study was to investigate the impact of selected legislative initiatives and their implementation for off-patent medicinal products in Slovakia compared with the rest of the Visegrád Group (V4 countries).Methods: We analyzed the development of applications for the reimbursement of generic and biosimilar drugs. Particular emphasis was placed on a) the availability and penetration of biosimilars from 2006 to 2020 in Slovakia, b) a comparative analysis of biosimilars in V4 countries based on the national reimbursement lists of medicinal products for August 2021. Data relating to the sales of generic and biosimilar medicines in Czechia, Hungary, Poland, and Slovakia were based on the IQVIA MIDAS MAT July 2021.Results: The number of applications for the reimbursement of generic drugs decreased from 296 in 2016 to 165 in 2020. In financial terms, the sales of generic medicines in Slovakia increased from 21.7% in 2015 to 22.3% in 2020. Over the same period, the sales of generic drugs in Poland fell from 40.4% in 2015 to 35.0% in 2020, from 26.2 to 22.1% in Hungary, and from 29.6 to 20.4% in Czechia. When considering the 66 biosimilars registered by the European Medicines Agency 38 drugs (58%) were available on the Slovak market as of August 1, 2021; this compared to 32 drugs (48%) in Poland, 38 drugs (58%) in Hungary, and 40 drugs (61%) in Czechia. In financial terms, the sales of biosimilars in Slovakia increased from 0.94% in 2015 to 2.00% in 2020. Over the same period, the sales of biosimilars in Poland increased from 0.59% in 2015 to 1.29% in 2020, from 0.72 to 2.23% in Hungary, and from 0.76 to 2.15% in Czechia.Conclusion: To intensify the use of generic and biosimilar medicines, we suggest the comprehensive re-evaluation of combinations of the three-threshold entry, the amount of mandatory price reductions, and external reference pricing requirements (as the average of the three lowest prices among the official prices of a medicinal product in other Member States) for generic and biosimilar drugs. We also suggest cancellation of the exception from the fixed co-payment of the insured.

show abstract

Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary

Cited by 11 publications

References 26 publications

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications

The long-term effects of the biolicit procedure for original and biosimilar GCSF and EPO products in Hungary

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

Contact Info

Product

Resources

About